Artemisinin resistance: current status and scenarios for containment
Key Points Malaria, caused by Plasmodium spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease. Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial. Owing...
Gespeichert in:
Veröffentlicht in: | Nature reviews. Microbiology 2010-04, Vol.8 (4), p.272-280 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 280 |
---|---|
container_issue | 4 |
container_start_page | 272 |
container_title | Nature reviews. Microbiology |
container_volume | 8 |
creator | Dondorp, Arjen M. Yeung, Shunmay White, Lisa Nguon, Chea Day, Nicholas P.J. Socheat, Duong von Seidlein, Lorenz |
description | Key Points
Malaria, caused by
Plasmodium
spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease.
Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial.
Owing to the use of artemisinin as a monotherapy, strains of
Plasmodium falciparum
have emerged that have a decreased sensitivity to the drug.
Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research.
Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control
Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread.
Artemisinin combination therapies are the first-line treatments for uncomplicated
Plasmodium falciparum
malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant
P. falciparum
malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment. |
doi_str_mv | 10.1038/nrmicro2331 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_744704898</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A222252169</galeid><sourcerecordid>A222252169</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</originalsourceid><addsrcrecordid>eNqF0U1PwyAYB3BiNE6nJ--m0YMHncIDlNbbMl-TJV70TBiFhWWlE9qD316WzmmMiVx4--Xh5Y_QCcHXBNPixofa6dAApWQHHRDB8Ihwyna3Y8gH6DDGBcbAuYB9NAAMuOAcH6C7cWhN7aLzzmfBRBdb5bW5zXQXgvFtluZtFzPlqyxq41VwTcxsEzLd-FY5Xyd0hPasWkZzvOmH6O3h_nXyNJq-PD5PxtORZgTaUa7UrNRgdVWKwoKtOFGCYMIgt8QKbatKVRVOK5YzYHjGElSUAmgsitLQIbro665C896Z2Mp0c22WS-VN00UpGBOYFWXxv6RUkJynfxqis19y0XTBp2dIAJYzmuM1Ou_RXC2NdN42bVB6XVKOITUOJC-TuuxVSiPGYKxcBVer8CEJluuo5I-okj7dHNzNalNt7Vc2CVz1IKYtPzfh-2Z_1fsEWw-d5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224643605</pqid></control><display><type>article</type><title>Artemisinin resistance: current status and scenarios for containment</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><source>Nature</source><creator>Dondorp, Arjen M. ; Yeung, Shunmay ; White, Lisa ; Nguon, Chea ; Day, Nicholas P.J. ; Socheat, Duong ; von Seidlein, Lorenz</creator><creatorcontrib>Dondorp, Arjen M. ; Yeung, Shunmay ; White, Lisa ; Nguon, Chea ; Day, Nicholas P.J. ; Socheat, Duong ; von Seidlein, Lorenz</creatorcontrib><description>Key Points
Malaria, caused by
Plasmodium
spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease.
Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial.
Owing to the use of artemisinin as a monotherapy, strains of
Plasmodium falciparum
have emerged that have a decreased sensitivity to the drug.
Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research.
Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control
Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread.
Artemisinin combination therapies are the first-line treatments for uncomplicated
Plasmodium falciparum
malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant
P. falciparum
malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment.</description><identifier>ISSN: 1740-1526</identifier><identifier>EISSN: 1740-1534</identifier><identifier>DOI: 10.1038/nrmicro2331</identifier><identifier>PMID: 20208550</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/326/22/1294 ; 631/326/417 ; 639/705 ; 692/699/255/1629 ; Antimalarials - therapeutic use ; Antiparasitic agents ; Artemisinins - chemistry ; Artemisinins - therapeutic use ; Biomedical and Life Sciences ; Cambodia ; Care and treatment ; Causes of ; Containment ; Diagnosis ; Disease Outbreaks - prevention & control ; Drug dosages ; Drug Resistance ; Drug resistance in microorganisms ; Drug therapy ; Genetic aspects ; Health aspects ; Infectious Diseases ; Life Sciences ; Malaria ; Malaria, Falciparum - drug therapy ; Malaria, Falciparum - epidemiology ; Medical Microbiology ; Medicine ; Microbiology ; Parasites ; Parasitology ; Plasmodium falciparum ; Plasmodium falciparum - pathogenicity ; review-article ; Sesquiterpenes ; Thailand ; Vector-borne diseases ; Virology</subject><ispartof>Nature reviews. Microbiology, 2010-04, Vol.8 (4), p.272-280</ispartof><rights>Springer Nature Limited 2010</rights><rights>COPYRIGHT 2010 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Apr 2010</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</citedby><cites>FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/nrmicro2331$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/nrmicro2331$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20208550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dondorp, Arjen M.</creatorcontrib><creatorcontrib>Yeung, Shunmay</creatorcontrib><creatorcontrib>White, Lisa</creatorcontrib><creatorcontrib>Nguon, Chea</creatorcontrib><creatorcontrib>Day, Nicholas P.J.</creatorcontrib><creatorcontrib>Socheat, Duong</creatorcontrib><creatorcontrib>von Seidlein, Lorenz</creatorcontrib><title>Artemisinin resistance: current status and scenarios for containment</title><title>Nature reviews. Microbiology</title><addtitle>Nat Rev Microbiol</addtitle><addtitle>Nat Rev Microbiol</addtitle><description>Key Points
Malaria, caused by
Plasmodium
spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease.
Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial.
Owing to the use of artemisinin as a monotherapy, strains of
Plasmodium falciparum
have emerged that have a decreased sensitivity to the drug.
Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research.
Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control
Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread.
Artemisinin combination therapies are the first-line treatments for uncomplicated
Plasmodium falciparum
malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant
P. falciparum
malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment.</description><subject>631/326/22/1294</subject><subject>631/326/417</subject><subject>639/705</subject><subject>692/699/255/1629</subject><subject>Antimalarials - therapeutic use</subject><subject>Antiparasitic agents</subject><subject>Artemisinins - chemistry</subject><subject>Artemisinins - therapeutic use</subject><subject>Biomedical and Life Sciences</subject><subject>Cambodia</subject><subject>Care and treatment</subject><subject>Causes of</subject><subject>Containment</subject><subject>Diagnosis</subject><subject>Disease Outbreaks - prevention & control</subject><subject>Drug dosages</subject><subject>Drug Resistance</subject><subject>Drug resistance in microorganisms</subject><subject>Drug therapy</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Infectious Diseases</subject><subject>Life Sciences</subject><subject>Malaria</subject><subject>Malaria, Falciparum - drug therapy</subject><subject>Malaria, Falciparum - epidemiology</subject><subject>Medical Microbiology</subject><subject>Medicine</subject><subject>Microbiology</subject><subject>Parasites</subject><subject>Parasitology</subject><subject>Plasmodium falciparum</subject><subject>Plasmodium falciparum - pathogenicity</subject><subject>review-article</subject><subject>Sesquiterpenes</subject><subject>Thailand</subject><subject>Vector-borne diseases</subject><subject>Virology</subject><issn>1740-1526</issn><issn>1740-1534</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqF0U1PwyAYB3BiNE6nJ--m0YMHncIDlNbbMl-TJV70TBiFhWWlE9qD316WzmmMiVx4--Xh5Y_QCcHXBNPixofa6dAApWQHHRDB8Ihwyna3Y8gH6DDGBcbAuYB9NAAMuOAcH6C7cWhN7aLzzmfBRBdb5bW5zXQXgvFtluZtFzPlqyxq41VwTcxsEzLd-FY5Xyd0hPasWkZzvOmH6O3h_nXyNJq-PD5PxtORZgTaUa7UrNRgdVWKwoKtOFGCYMIgt8QKbatKVRVOK5YzYHjGElSUAmgsitLQIbro665C896Z2Mp0c22WS-VN00UpGBOYFWXxv6RUkJynfxqis19y0XTBp2dIAJYzmuM1Ou_RXC2NdN42bVB6XVKOITUOJC-TuuxVSiPGYKxcBVer8CEJluuo5I-okj7dHNzNalNt7Vc2CVz1IKYtPzfh-2Z_1fsEWw-d5g</recordid><startdate>20100401</startdate><enddate>20100401</enddate><creator>Dondorp, Arjen M.</creator><creator>Yeung, Shunmay</creator><creator>White, Lisa</creator><creator>Nguon, Chea</creator><creator>Day, Nicholas P.J.</creator><creator>Socheat, Duong</creator><creator>von Seidlein, Lorenz</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BKSAR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PCBAR</scope><scope>PHGZM</scope><scope>PHGZT</scope><scope>PJZUB</scope><scope>PKEHL</scope><scope>PPXIY</scope><scope>PQEST</scope><scope>PQGLB</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>F1W</scope><scope>H95</scope><scope>H97</scope><scope>L.G</scope></search><sort><creationdate>20100401</creationdate><title>Artemisinin resistance: current status and scenarios for containment</title><author>Dondorp, Arjen M. ; Yeung, Shunmay ; White, Lisa ; Nguon, Chea ; Day, Nicholas P.J. ; Socheat, Duong ; von Seidlein, Lorenz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-6aab9c2fcd978f2fd51a7101426f1f7cfddadd0101f54240b4d97a3322c0789e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>631/326/22/1294</topic><topic>631/326/417</topic><topic>639/705</topic><topic>692/699/255/1629</topic><topic>Antimalarials - therapeutic use</topic><topic>Antiparasitic agents</topic><topic>Artemisinins - chemistry</topic><topic>Artemisinins - therapeutic use</topic><topic>Biomedical and Life Sciences</topic><topic>Cambodia</topic><topic>Care and treatment</topic><topic>Causes of</topic><topic>Containment</topic><topic>Diagnosis</topic><topic>Disease Outbreaks - prevention & control</topic><topic>Drug dosages</topic><topic>Drug Resistance</topic><topic>Drug resistance in microorganisms</topic><topic>Drug therapy</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Infectious Diseases</topic><topic>Life Sciences</topic><topic>Malaria</topic><topic>Malaria, Falciparum - drug therapy</topic><topic>Malaria, Falciparum - epidemiology</topic><topic>Medical Microbiology</topic><topic>Medicine</topic><topic>Microbiology</topic><topic>Parasites</topic><topic>Parasitology</topic><topic>Plasmodium falciparum</topic><topic>Plasmodium falciparum - pathogenicity</topic><topic>review-article</topic><topic>Sesquiterpenes</topic><topic>Thailand</topic><topic>Vector-borne diseases</topic><topic>Virology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dondorp, Arjen M.</creatorcontrib><creatorcontrib>Yeung, Shunmay</creatorcontrib><creatorcontrib>White, Lisa</creatorcontrib><creatorcontrib>Nguon, Chea</creatorcontrib><creatorcontrib>Day, Nicholas P.J.</creatorcontrib><creatorcontrib>Socheat, Duong</creatorcontrib><creatorcontrib>von Seidlein, Lorenz</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Earth, Atmospheric & Aquatic Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Earth, Atmospheric & Aquatic Science Database</collection><collection>ProQuest Central (New)</collection><collection>ProQuest One Academic (New)</collection><collection>ProQuest Health & Medical Research Collection</collection><collection>ProQuest One Academic Middle East (New)</collection><collection>ProQuest One Health & Nursing</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Applied & Life Sciences</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 3: Aquatic Pollution & Environmental Quality</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><jtitle>Nature reviews. Microbiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dondorp, Arjen M.</au><au>Yeung, Shunmay</au><au>White, Lisa</au><au>Nguon, Chea</au><au>Day, Nicholas P.J.</au><au>Socheat, Duong</au><au>von Seidlein, Lorenz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Artemisinin resistance: current status and scenarios for containment</atitle><jtitle>Nature reviews. Microbiology</jtitle><stitle>Nat Rev Microbiol</stitle><addtitle>Nat Rev Microbiol</addtitle><date>2010-04-01</date><risdate>2010</risdate><volume>8</volume><issue>4</issue><spage>272</spage><epage>280</epage><pages>272-280</pages><issn>1740-1526</issn><eissn>1740-1534</eissn><abstract>Key Points
Malaria, caused by
Plasmodium
spp., remains a tremendous disease burden worldwide, causing nearly one million deaths and 250 million cases of disease.
Artemisinin and artemisinin derivatives are effective antimalarials, especially when coupled with a second, unrelated antimalarial.
Owing to the use of artemisinin as a monotherapy, strains of
Plasmodium falciparum
have emerged that have a decreased sensitivity to the drug.
Several strategies to prevent the spread of the less resistant parasites have been put in place, such as a multifaceted approach that includes early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening of management and surveillance systems, and operations research.
Other, broader strategies can target the emergence and spread of drug resistance. These include mass drug administration, using multiple first-line therapies simultaneously, surveillance, active case investigation and focal control
Artemisinin is one of the few antimalarials for which there is no widespread resistance. However, malaria parasites with decreased sensitivity have been reported recently. In this Review Arjen Dondorp and colleagues describe the initial detection of artemisinin resistance and discuss several strategies to prevent its spread.
Artemisinin combination therapies are the first-line treatments for uncomplicated
Plasmodium falciparum
malaria in most malaria-endemic countries. Recently, partial artemisinin-resistant
P. falciparum
malaria has emerged on the Cambodia–Thailand border. Exposure of the parasite population to artemisinin monotherapies in subtherapeutic doses for over 30 years, and the availability of substandard artemisinins, have probably been the main driving force in the selection of the resistant phenotype in the region. A multifaceted containment programme has recently been launched, including early diagnosis and appropriate treatment, decreasing drug pressure, optimising vector control, targeting the mobile population, strengthening management and surveillance systems, and operational research. Mathematical modelling can be a useful tool to evaluate possible strategies for containment.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>20208550</pmid><doi>10.1038/nrmicro2331</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1740-1526 |
ispartof | Nature reviews. Microbiology, 2010-04, Vol.8 (4), p.272-280 |
issn | 1740-1526 1740-1534 |
language | eng |
recordid | cdi_proquest_miscellaneous_744704898 |
source | MEDLINE; Springer Nature - Complete Springer Journals; Nature |
subjects | 631/326/22/1294 631/326/417 639/705 692/699/255/1629 Antimalarials - therapeutic use Antiparasitic agents Artemisinins - chemistry Artemisinins - therapeutic use Biomedical and Life Sciences Cambodia Care and treatment Causes of Containment Diagnosis Disease Outbreaks - prevention & control Drug dosages Drug Resistance Drug resistance in microorganisms Drug therapy Genetic aspects Health aspects Infectious Diseases Life Sciences Malaria Malaria, Falciparum - drug therapy Malaria, Falciparum - epidemiology Medical Microbiology Medicine Microbiology Parasites Parasitology Plasmodium falciparum Plasmodium falciparum - pathogenicity review-article Sesquiterpenes Thailand Vector-borne diseases Virology |
title | Artemisinin resistance: current status and scenarios for containment |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T19%3A52%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Artemisinin%20resistance:%20current%20status%20and%20scenarios%20for%20containment&rft.jtitle=Nature%20reviews.%20Microbiology&rft.au=Dondorp,%20Arjen%20M.&rft.date=2010-04-01&rft.volume=8&rft.issue=4&rft.spage=272&rft.epage=280&rft.pages=272-280&rft.issn=1740-1526&rft.eissn=1740-1534&rft_id=info:doi/10.1038/nrmicro2331&rft_dat=%3Cgale_proqu%3EA222252169%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224643605&rft_id=info:pmid/20208550&rft_galeid=A222252169&rfr_iscdi=true |